Kura Oncology Stock News

Kura Oncology (NASDAQ:KURA) had its target price trimmed by Credit Suisse Group from $40.00 to $21.00 in a research report released on Friday morning, The Fly reports. The brokerage currently has an outperform rating on the stock. A number of other equities analysts have also issued reports on the stock. Wedbush reiterated an outperform rating []

Kura Oncology (NASDAQ:KURA) had its target price trimmed by Credit Suisse Group from $40.00 to $21.00 in a research report released on Friday, The Fly reports. The firm currently has an outperform rating on the stock. Other equities research analysts have also recently issued reports about the company. Zacks Investment Research upgraded Kura Oncology from []

NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. (Kura or the Company) (NASDAQ: KURA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The FDA has slapped a partial clinical hold on the early-stage program for one of Kura Oncology Incs (NASDAQ:

Shares of Kura Oncology, Inc. (NASDAQ:KURA) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $11.90 and last traded at $13.26, with a volume of 85180 shares changing hands. The stock had previously closed at $16.60. Several equities analysts have recently issued reports on the company. Wedbush […]

A partial clinical hold for the company's experimental leukemia treatment is making investors nervous.

Management to host webcast and conference call today at 8:30 a.m. ET Management to host webcast and conference call today at 8:30 a.m. ET

Equities analysts expect that Kura Oncology, Inc. (NASDAQ:KURA) will announce ($0.54) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Kura Oncologys earnings. The highest EPS estimate is ($0.51) and the lowest is ($0.62). Kura Oncology posted earnings per share of ($0.45) in the same []

SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences:

SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

Credit Suisse AG boosted its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 37.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,727 shares of the companys stock after acquiring an additional 15,625 shares during the quarter. Credit Suisse AG owned []

Credit Suisse AG boosted its position in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 37.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 57,727 shares of the companys stock after buying an additional 15,625 shares during the period. Credit Suisse AG []

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment